The introduction of magnetic stimulation to the central nervous system by Barker et al. in 1985 brought motor evoked potentials from the era of unbearable transcranial electrical stimulation to the era of painless and noninvasive transcranial magnetic stimulation, which is now routinely used in clinical practice and provides an indispensable neurophysiological method for the diagnosis and prognostic evaluation of many neurological disorders. Transcranial magnetic stimulation of motor evoked potentials is currently the only feasible neurophysiological tool for evaluating the central motor nervous system. It is mainly used as an aid in the diagnosis of neurological disorders involving motor function (e.g. motor neuron disease, multiple sclerosis) and in the prediction of outcome (e.g. ischemic cerebrovascular disease). The first case report of repetitive transcranial magnetic stimulation (rTMS) for depression was published in 1993, and the first article on repetitive transcranial magnetic stimulation for Parkinson’s disease was published in 1994. The first article on Parkinson’s disease was published in 1994; since then, there have been numerous studies on ischemic cerebrovascular disease, cognitive dysfunction (dementia), anxiety, obsessive-compulsive, migraine and even intractable epilepsy, as well as aphasia, dysphagia, tinnitus and other symptoms.